Following Merca East, Arno Pharma joins hands with Roche! Cooperate in the exploration of its two products in the study and PD-L1 monoantial joint drug use

As part of the collaboration, Ano Pharma will evaluate the safety, toadability and initial efficacy of the combined administration of AN0025, AN2025 and Roche Pharmaceutical Oncology immunotherapy drug Atilijudol.
the main purpose of this study was to determine the appropriate dose for both dose-limiting toxicity (DLT) and at the same time as attilijudant.
the dose finding (DLT) part, the purpose of the trial was to study the safety and effectiveness of triple drug use in patients with PIC3CA mutation.
the agreement, Roche Pharmaceuticals will provide acetic monoantigen for the clinical trial.
vision of Ano Pharmaceuticals is to turn cancer into a truly chronic disease by exploring 'cocktail' therapies that once again increase the effectiveness and cure rate of combination drugs on the basis of targeting and immunotherapy.
, through its partnerships with the world's leading pharmaceutical and biotechnology companies, as well as in-house research and development, has formed a pipeline with oncology immunotherapy at its core, covering more than a dozen targets and dedicated to innovative immunotherapy.
and led by a world-class team to rapidly develop products and conduct clinical trials around the world.
With this clinical cooperation with Roche, Ano Pharma has become one of the few pharmaceutical companies in China to achieve strategic cooperation with the two world pharmaceutical giants, in addition to this partnership with Roche, Ano and Mercado in AN0025 joint Keytruda® global multi-center Phase 1b clinical trials are also under way.
"We are excited to work clinically with Roche, the world's leading pharmaceutical company, and we look forward to bringing innovative therapies to patients with solid tumors worldwide through combination drug use."
Dr. Lars Birgerson, of Ano Pharmaceuticals, said the clinical collaboration with Roche involves two core products in the Arno pipeline and has the potential for a global "first in class."
looks forward to involving Ano Pharma in a global wave of innovation in the field of oncology immunotherapy by exploring the combined clinical trials of AN2025, AN0025 and Roche's PDL1 inhibitor Tecentriq.
the AN2025S0101 AN2025S0101 is a one-arm open, multi-center, Phase 1 dose exploration study to assess the safety, toerability and pharmacodynamics of AN2025 and AN0025 in patients with local late stage/metastasis solid tumors in a combined application with Atiliju monoantigen.
, the initial efficacy of these combined treatments will be evaluated.
the study included three restrictive toxicity (DLT) observation cycles, each of which will maintain a 21-day treatment cycle.
the study is expected to recruit 12-63 subjects, all of the patients in the group will be treated with a combined drug until the course of the disease progresses, either to produce insatiable toxicity, or to withdraw from the clinic.
clinical trial will begin in the United States and other regions.
About Ano Pharmaceuticals Ano Pharmaceuticals is a global biopharmaceutical company at the clinical stage dedicated to the development of differentiated and innovative oncology immunotherapy drugs.
currently has three clinical phase products and is rapidly conducting clinical trials around the world, led by a world-class team, with the AN2025 (Buparlisib) project qualified by the FDA as a fast track into the Global Phase III clinical trial of metastatic head and neck cancer disease; The intravenously administered lysosovirus AN1004 (Pelareorep) project is about to enter Phase 3 of the Global Multi-Center Clinic, and the Global Potential FIC Oncology Immune AN0025 (EP4 Antagonist) Project is currently in Phase 1b clinical in Europe and the United States.
Atezolizumab® a registered trademark of Genentech, a member of the Roche Group.